News Releases

CHICAGO, Nov. 28, 2017 /PRNewswire/ -- The importance of quantitative analysis in breast imaging was the focus of numerous abstracts accepted for presentation, here, at the 103rd Annual Radiological Society of North America (RSNA) meeting, November 26-December 1, 2017 (South #2571).  Four abstracts highlighted the use of Volpara Solutions' quantitative analysis tools for breast imaging. The tools provide actionable quantitative metrics for clinicians, including volumetric density, personalized dose, potential high risk, and other factors designed to maintain accuracy and drive consistent quality in breast screening.

Two research groups used Volpara to examine screening performance across density categories. In the study, "The Relationship between Quantitative Breast Density, Age and Cancer Detection Rate in a Large UK Breast Screening Population," (SSA01-03, Arie Crown Theater, Sunday, November 26, 11:05-11:15 AM), Louise Wilkinson and colleagues looked at the influence of age and density on the cancer detection rate (CDR) in the UK screening program. Researchers included 70,435 screening mammograms from 63,577 women with 557 cancers, for an overall CDR of 0.8 percent.  Breast density was assessed and categorized by Volpara Density Grades (VDG). The cohort was divided into nine age groups to compare CDR in the lowest (VDG 1) and highest (VDG 4) density women, stratified by age.  Results demonstrated that in younger women, extreme density (Volpara VDG4) appears to correspond to higher CDR, while the opposite is true for older women. The results suggest that the relationship between cancer detection rate and density may vary with age and thus age should be taken into account when stratifying women into different screening strategies based on density.

Additionally, results from the UK TOMMY trial established that screening sensitivity appears to be significantly increased for women with intermediate density (4.5% to 15.5% Volpara density) compared to those with very high or very low density. In the study, "Using Quantitative Analysis to Understand How Performance of Digital Breast Tomosynthesis Varies with Breast Density," (SPSH55B, Room E352, Thursday, November 30, 3-4 PM), the addition of Digital Breast Tomosynthesis (DBT) significantly increased the specificity of 2D for all breast density subgroups but only significantly increased sensitivity in patients with quantitative breast density in the middle ranges. The results suggest that DBT may not improve cancer detection in women with very low or very high breast density.

In "Radiation Dose from Tomosynthesis and Digital Mammography versus Quantitative Breast Density," (SSJ01-04, Arie Crown Theater, Tuesday, November 28, 3:30–3:40 PM), VolparaDensity was used to measure personalized radiation dose across VDGs on 4,764 digital breast tomosynthesis (DBT) and digital mammograms, obtained by the same acquisition system in the same breast compression. Results showed that the mean glandular dose (MGD) for the four breast density categories were higher with tomosynthesis than mammography.  However, the results also show an inverse relationship between VDG and dose in the DBT exams, and that the relative dose increase is higher for fatty breasts and lower for dense breasts.  

Melissa Hill, PhD, of Volpara presents results about a new contrast-to-noise ratio (CNR) metric in "A Contrast-to-Noise Ratio for Clinical Mammographic Images" (SSQ18-03, Room S403B, Thursday, November 30, 10:50–11:00 AM). The novel approach for objectively measuring CNR on clinical images (as opposed to phantom) shows near-perfect correlation to EUREF's current method of measuring CNR from phantom images. As the first description of an objective CNR measure that can be made directly from mammographic images, this technique may enable real-time and patient-specific image quality evaluation.  

Volpara Solutions will showcase its entire suite of quantitative breast imaging tools, including introducing near real-time positioning feedback, during RSNA.

About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand. Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaEnterprise software is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific x‑ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.

SOURCE Volpara Solutions